Toward a patient-centered value framework in oncology
Cet article décrit les différences méthodologiques entre plusieurs outils de grands organismes américains et européens de lutte contre le cancer, permettant d'évaluer le rapport coût-efficacité des traitements anti-cancéreux, et propose des pistes d'amélioration de ces outils
In their Viewpoint in this issue of JAMA, Chandra and colleagues1 compare 5 such frameworks for assessing the value of cancer drugs: the American Society of Clinical Oncology “Value Framework” (ASCO)2; the European Society for Medical Oncology “Magnitude of Clinical Benefit Scale” (ESMO)3; the Institute for Clinical and Economic Review “Value Assessment Framework” (ICER)4; the Memorial Sloan Kettering Cancer Center “Drug Abacus” (MSK)5; and the National Comprehensive Cancer Network “Evidence Blocks” (NCCN).6
JAMA , éditorial, 2015